{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:11:51Z","timestamp":1791389511854,"version":"4.3.3"},"reference-count":40,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Baricitinib, a selective Janus kinase (JAK) 1 and 2 inhibitor, has recently emerged as a therapeutic option for patients with severe alopecia areata (AA). The aim of this study was to identify clinical and biological predictors of early therapeutic response to baricitinib in patients with AA in real-world clinical practice. Methods: A retrospective cohort study was conducted including patients with AA initiating baricitinib between January 2022 and January 2025. Patients were stratified into early responders and non-early responders. Univariate and multivariate logistic regression analyses were performed to assess factors independently associated with early therapeutic response. Results: A total of 44 patients with AA treated with baricitinib were included, the majority being female (65.9%, 29\/44), with a mean age of 37.3 years (SD 16.1). Early responders accounted for 34.1% (15\/44) of the cohort. In multivariate analysis, early response to baricitinib was independently associated with a lower baseline Severity of Alopecia Tool (SALT) score, shorter disease duration, and elevated erythrocyte sedimentation rate (ESR) at baseline (p &lt; 0.05). Receiver Operating Characteristic (ROC) curve analyses were performed to determine optimal thresholds for predicting early therapeutic response: ESR \u2265 9 mm\/h, baseline SALT score \u2264 60%, and disease duration \u2264 7 years. Conclusions: Baseline stratification using easily obtainable clinical and laboratory parameters may help identify patients most likely to benefit from initiating treatment with baricitinib. Our findings support the existence of a therapeutic window of opportunity in AA, particularly in patients with lower disease burden, shorter disease duration, and elevated ESR values.<\/jats:p>","DOI":"10.3390\/jcm14207312","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T11:39:34Z","timestamp":1760701174000},"page":"7312","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Defining a Therapeutic Window of Opportunity in Alopecia Areata: Predictors of Early Response to Baricitinib"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8823-5575","authenticated-orcid":false,"given":"Daniel","family":"Mu\u00f1oz-Barba","sequence":"first","affiliation":[{"name":"Dermatology Unit, Hospital Universitario Virgen de las Nieves, 18012 Granada, Spain"},{"name":"Dermatology Department, School of Medicine, University of Granada, 18016 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3834-8633","authenticated-orcid":false,"given":"Carmen","family":"Garc\u00eda-Moronta","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Hospital Universitario Virgen de las Nieves, 18012 Granada, Spain"},{"name":"Dermatology Department, School of Medicine, University of Granada, 18016 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5040-8483","authenticated-orcid":false,"given":"Alberto","family":"Soto-Moreno","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Hospital Universitario Virgen de las Nieves, 18012 Granada, Spain"},{"name":"Dermatology Department, School of Medicine, University of Granada, 18016 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3626-1558","authenticated-orcid":false,"given":"Manuel","family":"S\u00e1nchez-D\u00edaz","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Hospital Universitario Virgen de las Nieves, 18012 Granada, Spain"},{"name":"Dermatology Department, School of Medicine, University of Granada, 18016 Granada, Spain"},{"name":"Institute of Biosanitary Research IBS, 18012 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4186-1435","authenticated-orcid":false,"given":"Salvador","family":"Arias-Santiago","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Hospital Universitario Virgen de las Nieves, 18012 Granada, Spain"},{"name":"Dermatology Department, School of Medicine, University of Granada, 18016 Granada, Spain"},{"name":"Institute of Biosanitary Research IBS, 18012 Granada, Spain"},{"name":"Trichology Clinic, Hospital Universitario Virgen de las Nieves, 18012 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/12034754231168839","article-title":"Alopecia areata: An updated review for 2023","volume":"27","author":"Sibbald","year":"2023","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaad.2020.06.047","article-title":"Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: A systematic review","volume":"85","author":"Toussi","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2147\/CCID.S376096","article-title":"Alopecia areata: Burden of disease, approach to treatment, and current unmet needs","volume":"16","author":"Alhanshali","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Wei, D., Chen, Y., Shen, Y., Xie, B., and Song, X. (2023). Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: A network meta-analysis. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1152513"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ard.2025.01.024","article-title":"Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases: A systematic literature review informing the 2024 update of an international expert consensus statement","volume":"84","author":"Konzett","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Lensing, M., and Jabbari, A. (2022). An overview of JAK\/STAT pathways and JAK inhibition in alopecia areata. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.955035"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40257-023-00764-w","article-title":"Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2)","volume":"24","author":"Kwon","year":"2023","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_8","first-page":"CD013719","article-title":"Treatments for alopecia areata: A network meta-analysis","volume":"10","author":"Herranz","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e919","DOI":"10.1111\/jdv.20657","article-title":"Real-life effectiveness and safety of baricitinib in adults with alopecia areata: A multicentre study","volume":"39","author":"Mourtada","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2444494","DOI":"10.1080\/09546634.2024.2444494","article-title":"Baricitinib for the treatment of severe alopecia areata: Results from a 52-week multicenter retrospective real-world study","volume":"36","author":"Vignoli","year":"2025","journal-title":"J. Dermatol. Treat."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/jdv.20312","article-title":"Real-life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24-week Italian study","volume":"39","author":"Piraccini","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2268764","DOI":"10.1080\/09546634.2023.2268764","article-title":"Effectiveness and safety of baricitinib in patients with severe alopecia areata: A 36-week multicenter real-world experience","volume":"34","author":"Gargiulo","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/1346-8138.17641","article-title":"Predictive factors for treatment responses to baricitinib in severe alopecia areata: A retrospective, multivariate analysis of 70 cases from a single center","volume":"52","author":"Takahashi","year":"2025","journal-title":"J. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s40257-024-00884-x","article-title":"Predictors and management of inadequate response to JAK inhibitors in alopecia areata","volume":"25","author":"Zhang","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jaad.2016.08.042","article-title":"SALT II: A new take on the Severity of Alopecia Tool (SALT) for determining percentage scalp hair loss","volume":"75","author":"Olsen","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/bjd\/ljad253","article-title":"When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: Insights from trajectories analyses of patients enrolled in two phase III trials","volume":"189","author":"King","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Albayrak, H. (2023). Neutrophil-to-lymphocyte ratio, neutrophil-to-monocyte ratio, platelet-to-lymphocyte ratio, and systemic immune-inflammation index in psoriasis patients: Response to treatment with biological drugs. J. Clin. Med., 12.","DOI":"10.20944\/preprints202308.0347.v1"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/ijd.16744","article-title":"The role of new inflammatory markers in determining disease activation and severity in patients with hidradenitis suppurativa","volume":"62","author":"Cinar","year":"2023","journal-title":"Int. J. Dermatol."},{"key":"ref_19","first-page":"325","article-title":"Utilidad diagn\u00f3stica de la velocidad de sedimentaci\u00f3n globular","volume":"39","year":"2002","journal-title":"Med. Integral."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"103339","DOI":"10.1016\/j.autrev.2023.103339","article-title":"Biomarkers in alopecia areata: A systematic review and meta-analysis","volume":"22","author":"Zaaroura","year":"2023","journal-title":"Autoimmun. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI): A simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S344","DOI":"10.1016\/j.jid.2023.09.075","article-title":"Patterns of clinical response in patients with alopecia areata (AA) treated with ritlecitinib in the ALLEGRO phase 2b\/3 and ongoing, phase 3, ALLEGRO-LT studies","volume":"143","author":"King","year":"2023","journal-title":"J. Investig. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jamadermatol.2022.6085","article-title":"Prevalence and odds of depressive and anxiety disorders and symptoms in children and adults with alopecia areata: A systematic review and meta-analysis","volume":"159","author":"Lauron","year":"2023","journal-title":"JAMA Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"adv12425","DOI":"10.2340\/actadv.v103.12425","article-title":"Effectiveness and predictive factors of response to tofacitinib therapy in 125 patients with alopecia areata: A single-centre real-world retrospective study","volume":"103","author":"Huang","year":"2023","journal-title":"Acta. Derm. Venereol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1007\/s13555-023-01030-x","article-title":"Real-life effectiveness and tolerance of baricitinib for the treatment of severe alopecia areata with 1-year follow-up data","volume":"13","author":"Thirion","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e2024193","DOI":"10.5826\/dpc.1403a193","article-title":"Evaluation of serum inflammatory markers and their relationship to treatment response in alopecia areata patients","volume":"14","author":"Komurcugil","year":"2024","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"576","DOI":"10.36849\/JDD.7424","article-title":"Cross-sectional study of psoriasis, atopic dermatitis, rosacea, and alopecia areata suggests association with cardiovascular diseases","volume":"22","author":"Pagan","year":"2023","journal-title":"J. Drugs Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2147\/DDDT.S334727","article-title":"Evaluating the therapeutic potential of ritlecitinib for the treatment of alopecia areata","volume":"16","author":"Tosti","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s40257-023-00808-1","article-title":"Alopecia areata: Current treatments and new directions","volume":"24","author":"Dahabreh","year":"2023","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/jocd.13131","article-title":"Evaluation of complete blood cell and inflammatory parameters in patients with alopecia areata: Their association with disease severity","volume":"19","year":"2020","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.5604\/17322693.1184460","article-title":"Activity of JAK\/STAT and NF-kB in patients with axial spondyloarthritis","volume":"69","author":"Sokolik","year":"2015","journal-title":"Postep. Hig. I Med. Dosw. (Online)"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/acr.23585","article-title":"Tofacitinib in rheumatoid arthritis: Lack of early change in disease activity and the probability of achieving low disease activity at month 6","volume":"71","author":"Lee","year":"2019","journal-title":"Arthritis Care Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3904\/kjim.2022.369","article-title":"Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis","volume":"38","author":"Cho","year":"2023","journal-title":"Korean J. Intern. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/jdv.19665","article-title":"Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2","volume":"38","author":"Senna","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s12016-021-08883-0","article-title":"Alopecia areata: An update on etiopathogenesis, diagnosis, and management","volume":"61","author":"Zhou","year":"2021","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1111\/jdv.19822","article-title":"Baricitinib in alopecia areata: Real-world data from a case series in Greece","volume":"38","author":"Katoulis","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"adv18348","DOI":"10.2340\/actadv.v104.18348","article-title":"Baricitinib therapy for moderate to severe alopecia areata: A retrospective review of 95 Japanese patients","volume":"104","author":"Numata","year":"2024","journal-title":"Acta Derm Venereol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1111\/ijd.17722","article-title":"Effectiveness of baricitinib in alopecia areata patients with a current episode lasting longer than 8 years: An Italian multicenter real-life experience in the Lazio region","volume":"64","author":"Caldarola","year":"2025","journal-title":"Int. J. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Taylor, P.C., Laedermann, C., Alten, R., Feist, E., Choy, E., Haladyj, E., Deberdt, W., Kanik, K.S., Genovese, M.C., and O\u2019Shea, J.J. (2023). A JAK inhibitor for treatment of rheumatoid arthritis: The baricitinib experience. J. Clin. Med., 12.","DOI":"10.3390\/jcm12134527"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/ijd.17732","article-title":"Safety profile of baricitinib in patients with severe alopecia areata: A prospective study","volume":"64","author":"Bongiovanni","year":"2025","journal-title":"Int. J. Dermatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/20\/7312\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T12:15:29Z","timestamp":1760703329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/20\/7312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":40,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["jcm14207312"],"URL":"https:\/\/doi.org\/10.3390\/jcm14207312","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]}}}